May 9th 2025
Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Burst CME™: Stepping Up Care for Patients With PAH
View More
New Clinical Trials To Test Monoclonal Antibodies for Prevention of Widespread Bacterial Infections
March 9th 2018The Antibacterial Resistance Leadership Group (ARLG) is working to enroll patients in clinical trials of 2 investigational monoclonal antibodies, with the ultimate goal of reducing antimicrobial resistance.
Read More
Senate Bill Calls for $1 Billion To Go Towards Universal Flu Vaccine Research
February 28th 2018A new bill introduced by a group of senators aims to boost universal flu vaccine research by $1 billion over the next 5 years, as health officials continue to investigate the cause of the flu shot’s low efficacy.
Read More